Novel Study of Next-Generation BCMA-Targeted CAR-Modified T Cells for Multiple Myeloma Opens at MSK – OncLive
OncLive |
Novel Study of Next-Generation BCMA-Targeted CAR-Modified T Cells for Multiple Myeloma Opens at MSK
OncLive Chimeric antigen receptor (CAR) T-cell therapy has been developed as a novel strategy whereby the immune system functions as the "drug" against cancer—by taking out a patient's own T cells from peripheral blood, inserting a so called "vector" in the T … |
